Memantina Aurobindo

Memantine Hydrochloride, the active ingredient in Memantina Aurobindo, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease and dementia associated with Alzheimer’s disease in adult patients.

GNH USA supplies Memantina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Aurobindo is an NMDA‑receptor antagonist used in the management of Alzheimer‑related cognitive disorders.

- Moderate to severe Alzheimer’s disease: Improves cognition, memory and daily functional abilities. - Dementia associated with Alzheimer’s disease: Helps maintain functional independence. - Alzheimer’s‑related neuropsychiatric symptoms: May reduce agitation and aggression in some patients.

Memantina Aurobindo may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Cardiac arrhythmias - Hepatic dysfunction - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hypotension - Neuroleptic malignant‑like syndrome

When prescribing Memantina Aurobindo, clinicians should consider several safety factors.

- Renal impairment: Monitor renal function and adjust therapy as needed. - History of seizures: Evaluate risk and observe for seizure activity. - Cardiovascular disease: Monitor blood pressure and heart rhythm regularly. - Concomitant NMDA antagonists: Avoid combined use to prevent additive neurotoxicity. - Pregnancy and lactation: Safety unknown; use only if potential benefit justifies the risk. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Memantina Aurobindo can interact with other medicines that affect the central nervous system or cardiovascular system.

Major Interactions (Avoid): - Amantadine: Increases risk of CNS adverse effects. - Ketamine: Additive NMDA antagonism may lead to excessive neuroinhibition. - Other NMDA antagonists: Combined use can cause severe neurotoxicity.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: May enhance hypotensive effect. - Diuretics: Potential electrolyte disturbances. - CNS depressants (e.g., benzodiazepines): May increase sedation and dizziness.